{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:18:09Z","timestamp":1791235089537,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejmech.2025.118457","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:31:26Z","timestamp":1764894686000},"page":"118457","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Design, synthesis and biological evaluation of novel FXIa inhibitors featuring five-membered heterocycles as P2\u2019 fragments"],"prefix":"10.1016","volume":"303","author":[{"given":"Jie","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huachao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonghui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118457_bib1","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.mehy.2004.08.023","article-title":"Can thromboembolism be the result, rather than the inciting cause, of acute vascular events such as stroke, pulmonary embolism, mesenteric ischemia, and venous thrombosis?: a maladaptation of the prehistoric trauma response","volume":"64","author":"Yun","year":"2005","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.ejmech.2025.118457_bib2","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1586\/erc.10.61","article-title":"New-onset atrial fibrillation and acute coronary syndrome","volume":"8","author":"Lau","year":"2010","journal-title":"Expert Rev. Cardiovasc Ther."},{"key":"10.1016\/j.ejmech.2025.118457_bib3","doi-asserted-by":"crossref","first-page":"227","DOI":"10.5694\/mja2.50004","article-title":"New guidelines from the thrombosis and haemostasis society of Australia and New Zealand for the diagnosis and management of venous thromboembolism","volume":"210","author":"Tran","year":"2019","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.ejmech.2025.118457_bib4","first-page":"387","article-title":"Microbial modulation of coagulation disorders in venous thromboembolism, J. Inflamm","volume":"13","author":"Lichota","year":"2020","journal-title":"Res."},{"key":"10.1016\/j.ejmech.2025.118457_bib5","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1440-1797.2009.01128.x","article-title":"Review article: coagulation cascade and therapeutics update: relevance to nephrology. Part 1: overview of coagulation, thrombophilias and history of anticoagulants","volume":"14","author":"Adams","year":"2009","journal-title":"Nephrology"},{"key":"10.1016\/j.ejmech.2025.118457_bib6","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1538-7836.2008.02864.x","article-title":"Recollections on thrombin generation","volume":"6","author":"Hemker","year":"2008","journal-title":"J. Thromb. Haemost"},{"key":"10.1016\/j.ejmech.2025.118457_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1161\/ATVBAHA.118.310960","article-title":"Advances in antithrombotic therapy","volume":"39","author":"Weitz","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejmech.2025.118457_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23082002","article-title":"Fragment-Based lead generation of 5-Phenyl-1H-pyrazole-3-carboxamide derivatives as leads for potent factor Xia inhibitors","volume":"23","author":"Wei","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118457_bib9","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1055\/a-1384-3715","article-title":"Factor XI as a target for new anticoagulants","volume":"41","author":"Fredenburgh","year":"2021","journal-title":"H\u00e4mostaseologie"},{"key":"10.1016\/j.ejmech.2025.118457_bib10","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1021\/acs.jmedchem.1c00613","article-title":"Discovery of Milvexian, a High-Affinity, orally bioavailable inhibitor of factor XIa in clinical studies for antithrombotic therapy","volume":"65","author":"Dilger","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118457_bib11","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1182\/blood.2023020722","article-title":"Targeting factor XI and factor XIa to prevent thrombosis","volume":"143","author":"Gailani","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118457_bib12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/14728214.2023.2192923","article-title":"A review of emerging factor XI inhibitors","volume":"28","author":"Elsheikh","year":"2023","journal-title":"Expert. Opin. Emerg. Drugs"},{"key":"10.1016\/j.ejmech.2025.118457_bib13","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1538-7836.2005.01236.x","article-title":"Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice","volume":"3","author":"Wang","year":"2005","journal-title":"J. Thromb. Haemost"},{"issue":"Suppl 4","key":"10.1016\/j.ejmech.2025.118457_bib14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/hae.12402","article-title":"Rare bleeding disorders - bleeding assessment tools, laboratory aspects and phenotype and therapy of FXI deficiency","volume":"20","author":"James","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.ejmech.2025.118457_bib15","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/jth.15700","article-title":"Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa","volume":"20","author":"Heitmeier","year":"2022","journal-title":"J. Thromb. Haemost"},{"key":"10.1016\/j.ejmech.2025.118457_bib16","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1080\/17460441.2017.1384811","article-title":"Discovery methods of coagulation-inhibiting drugs","volume":"12","author":"G\u00f3mez-Outes","year":"2017","journal-title":"Expert. Opin. Drug. Discov"},{"key":"10.1016\/j.ejmech.2025.118457_bib17","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/bcp.13520","article-title":"First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in Non-Japanese and Japanese healthy subjects","volume":"84","author":"Perera","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118457_bib18","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13787","article-title":"Pharmacokinetics, pharmacodynamics, and safety of frunexian in healthy Chinese volunteer adults: a randomized dose-escalation phase I study","volume":"17","author":"Zhang","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.ejmech.2025.118457_bib19","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1111\/bcp.14732","article-title":"ONO-7684 a novel oral FXIa inhibitor: safety, tolerability, pharmacokinetics and pharmacodynamics in a first-in-human study","volume":"87","author":"Beale","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118457_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113437","article-title":"Design, synthesis and biological evaluation of novel FXIa inhibitors with 2-phenyl-1H-imidazole-5-carboxamide moiety as P1 fragment","volume":"220","author":"Lei","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118457_bib21","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1111\/jth.15439","article-title":"First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa","volume":"19","author":"Thomas","year":"2021","journal-title":"J. Thromb. Haemost"},{"key":"10.1016\/j.ejmech.2025.118457_bib22","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/CIRCULATIONAHA.122.062353","article-title":"Pharmacology and clinical development of factor XI inhibitors","volume":"147","author":"Greco","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.ejmech.2025.118457_bib23","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1080\/14656566.2022.2149323","article-title":"Pharmacotherapy for stroke prevention in nonvalvular atrial fibrillation: current strategies and future directions","volume":"23","author":"G\u00f3mez-Outes","year":"2022","journal-title":"Expert. Opin. Pharmacother"},{"key":"10.1016\/j.ejmech.2025.118457_bib24","article-title":"Factor XI\/XIa inhibition: the arsenal in development for a new therapeutic target in Cardio- and cerebrovascular disease","volume":"9","author":"Badimon","year":"2022","journal-title":"J. Cardiovasc. Dev. Dis."},{"key":"10.1016\/j.ejmech.2025.118457_bib25","doi-asserted-by":"crossref","first-page":"12203","DOI":"10.1021\/acs.jmedchem.3c00795","article-title":"Design and Preclinical characterization program toward Asundexian (BAY 2433334), an oral factor XIa inhibitor for the prevention and treatment of thromboembolic disorders","volume":"66","author":"Roehrig","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118457_bib26","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","article-title":"Why 90% of clinical drug development fails and how to improve it?","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2025.118457_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112137","article-title":"Discovery and development of plasma kallikrein inhibitors for multiple diseases","volume":"190","author":"Xie","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118457_bib28","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1021\/acs.jmedchem.1c02153","article-title":"Targeting the S2 subsite enables the structure-based discovery of novel highly selective factor XIa inhibitors","volume":"65","author":"Yao","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118457_bib29","doi-asserted-by":"crossref","first-page":"7611","DOI":"10.1021\/acs.jmedchem.5b00229","article-title":"Strategies for the discovery of target-specific or isoform-selective modulators","volume":"58","author":"Zhan","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118457_bib30","doi-asserted-by":"crossref","first-page":"8088","DOI":"10.1021\/acs.jmedchem.0c00279","article-title":"Structure-based design and preclinical characterization of selective and orally bioavailable factor XIa inhibitors: demonstrating the power of an integrated S1 protease family approach","volume":"63","author":"Lorthiois","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118457_bib31","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1007\/s11030-024-11024-2","article-title":"Structure-based design and synthesis of novel FXIa inhibitors targeting the S2' subsite for enhanced antithrombotic efficacy","volume":"29","author":"Wu","year":"2025","journal-title":"Mol. Divers."},{"key":"10.1016\/j.ejmech.2025.118457_bib32","doi-asserted-by":"crossref","first-page":"12290","DOI":"10.1021\/acs.jmedchem.0c00530","article-title":"Amide bond bioisosteres: strategies, synthesis, and successes","volume":"63","author":"Kumari","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118457_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.201800290","article-title":"Design and synthesis of imidazolidinone derivatives as potent anti-leishmanial agents by bioisosterism","volume":"352","author":"Ramu","year":"2019","journal-title":"Arch. Pharm (Weinheim)"},{"key":"10.1016\/j.ejmech.2025.118457_bib34","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/cbdd.14239","article-title":"Silicon switch: Carbon-silicon Bioisosteric replacement as a strategy to modulate the selectivity, physicochemical, and drug-like properties in anticancer pharmacophores","volume":"102","author":"Fotie","year":"2023","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2025.118457_bib35","doi-asserted-by":"crossref","first-page":"7677","DOI":"10.1021\/acs.jmedchem.6b00247","article-title":"2,3-Triazoles as amide bioisosteres: discovery of a new class of potent HIV-1 vif antagonists","volume":"59","author":"Mohammed","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118457_bib36","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1016\/j.bmcl.2012.05.078","article-title":"'Click' synthesis of a triazole-based inhibitor of Met functions in cancer cells","volume":"22","author":"Colombo","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2025.118457_bib37","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1016\/j.bmc.2004.07.012","article-title":"Synthesis of chroman analogues of lipoic acid and evaluation of their activity against reperfusion arrhythmias","volume":"12","author":"Koufaki","year":"2004","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118457_bib38","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.1021\/jm010962w","article-title":"Novel potent inhibitors of lipid peroxidation with protective effects against reperfusion arrhythmias","volume":"44","author":"Koufaki","year":"2001","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118457_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113474","article-title":"Design, synthesis of novel celastrol derivatives and study on their antitumor growth through HIF-1\u03b1 pathway","volume":"220","author":"Shang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118457_bib40","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1016\/j.bmc.2017.03.055","article-title":"Design, synthesis, and biological activity of novel tetrahydropyrazolopyridone derivatives as FXa inhibitors with potent anticoagulant activity","volume":"25","author":"Sun","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118457_bib41","doi-asserted-by":"crossref","first-page":"5646","DOI":"10.1016\/j.bmc.2016.09.024","article-title":"Design, synthesis, and structure-activity relationship of novel and effective apixaban derivatives as FXa inhibitors containing 1,2,4-triazole\/pyrrole derivatives as P2 binding element","volume":"24","author":"Wang","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118457_bib42","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.bmc.2017.01.039","article-title":"Novel 6-methoxycarbonyl indolinones bearing a pyrrole Mannich base moiety as angiokinase inhibitors","volume":"25","author":"Qin","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118457_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115242","article-title":"Design, synthesis, and biological evaluation of novel dihydropteridone derivatives possessing oxadiazoles moiety as potent inhibitors of PLK1","volume":"251","author":"Li","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118457_bib44","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1021\/jf047985e","article-title":"Syntheses, antifeedant activity, and QSAR analysis of new oxa(thia)diazolyl 3(2H)-pyridazinones","volume":"53","author":"Cao","year":"2005","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.ejmech.2025.118457_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116813","article-title":"Design, synthesis, and evaluation of antitumor activity in Pseudolaric acid B Azole derivatives: novel and potent angiogenesis inhibitor via regulation of the PI3K\/AKT and MAPK mediated HIF-1\/VEGF signaling pathway","volume":"278","author":"Deng","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118457_bib46","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1016\/j.bmcl.2016.07.068","article-title":"Synthesis and bioactivities of novel pyrazole oxime derivatives containing a 1,2,3-thiadiazole moiety","volume":"26","author":"Dai","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2025.118457_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.951713","article-title":"Synthesis and evaluation of anticancer activity of quillaic acid derivatives: a cell cycle arrest and apoptosis inducer through NF-\u03baB and MAPK pathways","volume":"10","author":"Huang","year":"2022","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejmech.2025.118457_bib48","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1016\/j.jmb.2019.09.008","article-title":"Allosteric inhibition as a new mode of action for BAY 1213790, a neutralizing antibody targeting the activated form of coagulation factor XI","volume":"431","author":"Schaefer","year":"2019","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2025.118457_bib49","doi-asserted-by":"crossref","first-page":"5332","DOI":"10.1021\/acs.jmedchem.2c02130","article-title":"Factor XIa inhibitors in anticoagulation therapy: recent advances and perspectives","volume":"66","author":"Xie","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118457_bib50","article-title":"Ferric chloride-induced murine thrombosis models","volume":"115","author":"Li","year":"2016","journal-title":"J. Vis. Exp."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342501222X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342501222X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T04:48:34Z","timestamp":1781326114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352342501222X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":50,"alternative-id":["S022352342501222X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118457","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and biological evaluation of novel FXIa inhibitors featuring five-membered heterocycles as P2\u2019 fragments","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118457","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118457"}}